Methods for detecting or reducing the incidence of adverse drug reactions
OwnerJean-Claude ROUJEAU (deceased), Wen-Hung CHUNG +1inventors
InventorsJean-Claude ROUJEAU (deceased), Wen-Hung CHUNG, Maja MOCKENHAUPT
Life of this patent
Estimating the term…
Abstract
Methods for assessing the risk of developing adverse drug reaction in a subject in need of such assessment are provided, comprising the step of detecting the presence of an HLA-B allele in a sample obtained from the subject, wherein the presence of allele is indicative of the subject having an increased risk of developing the adverse drug reaction. Also provided are methods of treating or reducing the incidence of the adverse drug reaction.
Claims17
A method of assessing a risk for developing an adverse drug reaction in a subject, comprising the steps of
- (a) detecting the presence of HLA-B*57:01 allele, HLA-B*38:01 allele or the combination thereof in the sample of the subject, and
- (b) identifying the subject as having an increased risk of developing the adverse drug reaction if the HLA-B*57:01 allele, HLA-B*38:01 allele or the combination thereof is present.
A method for assessing the risk of developing an adverse drug reaction and treating the adverse drug reaction, comprising the steps of
- (a) detecting the presence of an HLA-B*57:01 allele, an HLA-B*38:01 allele or the combination thereof in the sample of the subject;
- (b) identifying the subject as having an increased risk of developing the cutaneous adverse drug reaction if the HLA-B*57:01 allele, HLA-B*38:01 allele or the combination thereof is present;
- and
- (c) administering a medication to treat the adverse drug reaction.
A method for assessing the risk of developing an adverse drug reaction and reducing the incidence of the adverse drug reaction, comprising the steps of:
- (a) detecting the presence of an HLA-B*57:01 allele, an HLA-B*38:01 allele or the combination thereof in the sample of the subject;
- (b) identifying the subject as having an increased risk of developing the cutaneous adverse drug reaction if the HLA-B*57:01 allele, the HLA-B*38:01 allele or the combination thereof is present;
- and
- (c) administering a treatment that is not an anticonvulsant.
The use of an agent for detecting the HLA-B*57:01 allele, an HLA-B*38:01 allele or the combination thereof in the manufacture of a diagnostic kit to evaluate the risk of developing an adverse drug reaction induced by an anti-convulsant.
Dependencies are inferred from the claim text.